Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
41
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
OrthoPediatrics
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
International Clinic Openings And Product Launches Will Expand Global Reach
Key Takeaways Global expansion, regulatory approvals, and clinic growth are expected to strengthen market position, unlock new revenue streams, and reduce compliance risks. Ongoing innovation, specialty bracing synergies, and enhanced surgeon partnerships are poised to boost market share, margins, and long-term recurring revenue.
View narrative
US$33.86
FV
43.3% undervalued
intrinsic discount
16.96%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
1 day ago
author updated this narrative
Equitas Small Finance Bank
AN
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
Rebalancing Loan Portfolios And Investing In Tech Will Optimize Operations
Key Takeaways Strategic shift from Microfinance to Small Business and Used Vehicle finance could stabilize credit costs and enhance revenue through profitable growth. Technology investments' completion and deposit repricing may improve net margins, supporting earnings potential and enhanced RoA by FY '26.
View narrative
₹67.28
FV
21.3% undervalued
intrinsic discount
14.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
20
users have followed this narrative
Updated
narrative
Expedia Group
AN
AnalystConsensusTarget
Consensus Narrative from 33 Analysts
Emerging Asian Markets And AI Will Expand Global Reach
Key Takeaways Geographic and technological diversification, including AI and digital channels, are fueling growth, improved retention, and expanding Expedia's market opportunity. Strong B2B momentum and loyalty strategies are driving stable, high-margin revenue streams and improving long-term earnings resilience.
View narrative
US$222.00
FV
6.6% undervalued
intrinsic discount
6.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
29
users have followed this narrative
2 days ago
author updated this narrative
Core Natural Resources
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Rising AI Demand And US Policy Will Drive Coal Success
Key Takeaways Rising energy demand and favorable regulatory changes position the company for sustained revenue growth and improved profitability through enhanced sales and competitive operations. Strong execution on cost efficiencies, flexible market strategy, and shareholder returns are expected to drive margin expansion, stable cash flow, and increased intrinsic value.
View narrative
US$94.75
FV
25.1% undervalued
intrinsic discount
15.85%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
2 days ago
author updated this narrative
Oncology Institute
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Florida And Nevada Expansions Will Strengthen Community Oncology Care
Key Takeaways Rapid expansion of value-based contracts and scaled risk-based care models is driving strong patient growth, margin expansion, and sustainable top-line gains. Market tailwinds, tech investments, and growing pharmacy operations position the company for durable demand, lower costs, and increased profitability.
View narrative
US$7.00
FV
46.3% undervalued
intrinsic discount
19.54%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
about 21 hours ago
author updated this narrative
Alchip Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 13 Analysts
North America HPC And AI Developments Will Broaden Horizons
Key Takeaways Growth in HPC and AI sectors, alongside strategic workforce expansion, positions Alchip for improved margins and operational efficiency. Advances in packaging and chiplet solutions, along with ADAS market exposure, support revenue sustainability despite projected revenue fluctuations.
View narrative
NT$4.35k
FV
1.1% undervalued
intrinsic discount
31.61%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
Constellium
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Aluminum Packaging And Recycling Will Create A Sustainable Future
Key Takeaways Sustainability-driven demand and recycling initiatives are expanding Constellium's market opportunities, enhancing volumes, pricing power, and profitability. Operational improvements and innovation in high-margin sectors are expected to drive margin growth and earnings resilience.
View narrative
US$18.31
FV
21.1% undervalued
intrinsic discount
9.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
1 day ago
author updated this narrative
908 Devices
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
US Federal And International Funding Will Expand Global Analysis Markets
Key Takeaways Expanding public and private sector funding, along with strong global demand, positions the company for accelerated growth and increased market share in molecular analysis devices. Operational improvements and a shift toward recurring revenue streams are expected to enhance margins, earnings stability, and reduce financial risk.
View narrative
US$10.00
FV
33.7% undervalued
intrinsic discount
5.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
1 day ago
author updated this narrative
Coherus Oncology
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Biosimilar Setbacks Will Curb Returns But Slight Hope Endures
Key Takeaways Heavy reliance on a few late-stage products and uncertain clinical outcomes create significant risk for both revenue and earnings sustainability. Downward pricing pressure, biosimilar competition, and slow product uptake threaten long-term profitability despite innovation and new market strategies.
View narrative
US$1.10
FV
4.5% undervalued
intrinsic discount
-51.15%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies